Nanotechnology based assays for validating protein biomarkers hot girl dating games
Targeted proteomics is homing in on promising biomarkers to help screen for cancer and guide patient treatment, but much work still needs to be done to validate these biomarkers and develop technology capable of bringing them to the clinic.
By Anne Harding Inclusion of companies in this article does not indicate endorsement by either AAAS or nor is it meant to imply that their products or services are superior to those of other companies.
"One of the critical issues is, of course, that measuring only a couple of hundred samples, control and case, would need to be done at a high enough throughput, and these measurements must be reproducible," says Ruedi Aebersold, a professor of systems biology at the Swiss Federal Institute of Technology in Zurich.Vermillion's OVA1, cleared by the FDA in 2009, measures five different proteins in the blood, and is not used to screen for ovarian cancer, but to help evaluate whether an ovarian mass is benign or malignant prior to surgery."What you've seen in the industry is a lot of great technological developments, but in terms of locking down and then validating there are very few of these tests that have really made it through that process and ultimately been commercialized and validated in clinical practice," says Paul Beresford, vice president of business development and strategic marketing at Biodesix, a molecular diagnostic company.The company has 12 assays in production and 54 in development."Clinical proteomics has been done for 50 years; people have had their serum proteins measured to detect disease for decades," says Stephen Kron, a professor of molecular genetics and cell biology at The University of Chicago.